Interaction of Ganoderma triterpenes with doxorubicin and proteomic characterization of the possible molecular targets of Ganoderma triterpenes

Cancer Science

Volumn 99, Issue 7, 2008, Pages 1461-1470

  Yue, Qing Xi ^a   Xie, Fu Bo ^a   Guan, Shu Hong ^a   Ma, Chao ^a   Yang, Min ^a   Jiang, Bao Hong ^a   Liu, Xuan ^a   Guo, De An ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GANODERMA LUCIDUM EXTRACT; LUCIDENIC ACID N; REACTIVE OXYGEN METABOLITE; TRITERPENE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; FLOW CYTOMETRY; HELA CELL; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANTIGENS, NUCLEAR; BLOTTING, WESTERN; CELL CYCLE; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG SYNERGISM; GANODERMA; HELA CELLS; HUMANS; NEOPLASM PROTEINS; PROTEIN PHOSPHATASE 2; PROTEOMICS; REACTIVE OXYGEN SPECIES; TRITERPENES;

EID: 44449168756     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00824.x     Document Type: Article

References (47)

1. Yun TK. Update from Asia. Asian studies on cancer chemoprevention. Ann NY Acad Sci 1999; 889: 157-92.
2. Sliva D. Cellular and physiological effects of Ganoderma lucidum (Reishi). Mini-Rev Med Chem 2004; 4: 873-9.
3. Sliva D. Ganoderma lucidum in cancer research. Leuk Res 2006; 30: 767-8.
4. Yuen JW, Gohel MD. Anticancer effects of Ganoderma lucidum: A review of scientific evidence. Nutr Cancer 2005; 53: 11-17.
5. Chen X, Hu ZP, Yang XX et al. Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer. Int Immunolpharmacol 2006; 6: 499-508.
6. Gao Y, Gao H, Chan E et al. Antitumor activity and underlying mechanisms of ganopoly, the refined polysaccharides extracted from Ganoderma lucidum, in mice. Immunol Invest 2005; 34: 171-98.
7. Hu H, Ahn NS, Yang X, Lee YS, Kang KS. Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cells. Int J Cancer 2002; 102: 250-3.
8. Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D. Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-κB signaling. Nutr Cancer 2004; 49: 209-16.
9. Jiang J, Slivova V, Valachovicova T, Harvey K, Sliva D. Ganoderma lucidum inhibits proliferation and induces apoptosis in human prostate cancer cells PC-3. Int J Oncol 2004; 24: 1093-100.
10. Kim KC, Kim JS, Son JK, Kim IG. Enhanced induction of mitochondrial damage and apoptosis in human leukemia HL-60 cells by the Ganoderma lucidum and Duchesnea chrysantha extracts. Cancer Lett 2007; 246: 210-17.
11. Lu QY, Jin YS, Zhang Q et al. Ganoderma lucidum extracts inhibit growth and induce actin polymerization in bladder cancer cells in.vitro. Cancer Lett 2004; 216: 9-20.
12. Muller CI, Kumagai T, O'Kelly J, Seeram NP, Heber D, Koeffler HP. Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells. Leuk Res 2006; 30: 841-8.
13. Xie JT, Wang CZ, Wicks S et al. Ganoderma lucidum extract inhibits proliferation of SW480 human colorectal cancer cells. Exp Oncol 2006; 28: 25-9.
14. Johnston N. Medicinal mushroom cuts off prostate cancer cells'blood supply. Drug Discov Today 2005; 10: 1584.
15. Slivova V, Valachovicova T, Jiang J, Sliva D. Ganoderma lucidum inhibits invasiveness of breast cancer cells. J Cancer Integr Med 2004; 2: 25-30.
16. Stanley G, Harvey K, Slivova V, Jiang J, Sliva D. Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-β1 from prostate cancer cells. Biochem Biophys Res Commun 2005; 330: 46-52.
17. Yeung WH, Lu QL, Zhang Q, Go VLW. Chemical and biochemical basis of the potential anti-tumor properties of Ganoderma lucidum. Curr Top Nutraceut Res 2004; 2: 67-77.
18. Kimura Y, Taniguchi M, Baba K. Antitumor and antimetastatic effects on liver triterpenoid fractions of Ganoderma lucidum: Mechanism of action and isolation of active substance. Anticancer Res 2002; 22: 3309-18.
19. Lin SB, Li CH, Lee SS, Kan LS. Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G 2 -phase cell cycle arrest. Life Sci 2003; 72: 2381-90.
20. Min BS, Gao JJ, Nakamura N, Hattori M. Triterpenes from the spores of Ganoderma lucidum and their cytotoxicity against meth-A and LLC tumor cells. Chem Pharm Bull 2000; 48: 1026-33.
21. Yang HL. Ganoderic acid produced from submerged culture of Ganoderma lucidum induces cell cycle arrest and cytotoxicity in human hepatoma cell line BEL7402. Biotechnol Lett 2005; 27: 835-8.
22. Wu TS, Shi LS, Kuo SC. Cytotoxicity of Ganoderma lucidum triterpenes. J Nat Prod 2001; 64: 1121-2.
23. Liu X, Fan XL, Zhao Y et al. Estrogen provides neuroprotection against activated microglia-induced dopaminergic neuronal injury through both estrogen receptor-α and estrogen receptor-β in microglia. J Neurosci Res 2005; 81: 653-65.
24. Chou TC, Talalay P. Analysis of combined drug effects: A new look at a very old problem. Trends Pharmacol Sci 1983; 4: 450-4.
25. Ma C, Guan SH, Yang M, Liu X, Guo DA. Differential protein expression in mouse splenic mononuclear cells treated with polysaccharides from spores of Ganoderma lucidum. Phytomedicine 2008; 15: 268-76.
26. Shen H, Cheng G, Fan H et al. Expressed proteome analysis of human hepatocellular carcinoma in nude mice (LCI-D20) with high metastasis potential. Proteomics 2006; 6: 528-37.
27. Liu X, Zhu XZ. Roles of p53, c-Myc, Bcl-2, Bax and caspases in glutamate-induced neuronal apoptosis and the possible neuroprotective mechanism of basic fibroblast growth factor. Brain Res Mol Brain Res 1999; 71: 210-16.
28. Wang H, Joseph JA. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Rad Biol Med 1999; 27: 612-16.
29. Shih SF, Wu YH, Hung CH, Yang HY, Lin JY. Abrin triggers cell death by inactivating a thiol-specific antioxidant protein. J Biol Chem 2001; 276: 21 870-7.
30. Fang L, Du Wang YD, Yang G et al. Cell polarity protein Par3 complexes with DNA-PK via Ku70 and regulates DNA double-strand break repair. Cell Res 2007; 17: 100-16.
31. Jankovic D, Pesic M, Markovi J et al. The combination of sulfinosine and 8-Cl-cAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in.vitro. Invest New Drugs 2006; 24: 15-25.
32. Shen H, Schultz M, Kruh GD, Tew KD. Increased expression of DNA-dependent protein kinase confers resistance to adriamycin. Biochim Biophys Acta 1998; 1381: 131-8.
33. Caraglia M, Budillon A, Vitale G, Lupoli G, Tagliaferri P, Abbruzzese A. Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation. Eur J Biochem 2000; 267: 3919-36.
34. Caraglia M, Marra M, Giuberti G et al. The role of eukaryotic initiation factor 5A in the control of cell proliferation and apoptosis. Amino Acids 2001; 20: 91-104.
35. Hermeking H, Benzinger A. 14-33 proteins in cell cycle regulation. Semin Cancer Biol 2006; 16: 183-92.
36. Battistoni A, Guarguaglini G, Degrassi F et al. Deregulated expression of the RanBP1 gene alters cell cycle progression in murine fibroblasts. J Cell Sci 1997; 110: 2345-57.
37. Guarguaglini G, Renzi L, D'Ottavio F et al. Regulated Ran-binding protein 1 activity is required for organization and function of the mitotic spindle in mammalian cells in.vivo. Cell Growth Differ 2000; 11: 455-65.
38. Janssens V, Goris J. Protein phosphatase 2A: A highly regulated family of serine/threonine phosphatases implicated in cell growth and signaling. Biochem J 2001; 353: 417-39.
39. Lin SS, Bassik MC, Suh H et al. PP2A regulates BCL-2 phosphorylation and proteasome mediated degradation at the endoplasmic reticulum. J Biol Chem 2006; 281: 23 003-12.
40. Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-22.
41. Chevallet M, Wagner E, Luche S, Dorsselaer A, Leize-Wagner E, Rabilloud T. Regeneration of peroxiredoxins during recovery after oxidative stress. J Biol Chem 2003; 278: 37 146-53.
42. 2 -induced cell death. J Biol Chem 2005; 280: 28 775-84.
43. Spagnolo L, Rivera-Calzada A, Pearl LH, Llorca O. Three-dimensional structure of the human DNA-PKcs/Ku70/Ku80 complex assembled on DNA and its implications for DNA DSB repair. Mol Cell 2006; 22: 511-19.
44. Ayene IS, Ford LP, Koch CJ. Ku protein targeting by Ku70 small interfering RNA enhances human cancer cell response to topoisomerase II inhibitor and γ radiation. Mol Cancer Ther 2005; 4: 529-36.
45. Yuan CC, Huang HC, Tsai LC, Ng HT, Huang TS. Cytokeratin-19 associated with apoptosis and chemosensitivity in human cervical cancer cells. Apoptosis 1997; 2: 101-5.
46. Yuan CC, Huang TS, Ng HT, Liu RS, Hung MW, Tsai LC. Elevated cytokeratin-19 expression associated with apoptotic resistance and malignant progression of human cervical carcinoma. Apoptosis 1998; 3: 161-9.
47. Torsten RD, Inga W, Manuela B, Gerhard F, Bernd K. Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling. DNA Repair 2003; 2: 49-60.